Narcolepsy Therapeutics Market Analysis and Forecast, 2022-2032

The global  narcolepsy therapeutics market  is projected to reach $4,912.3 million by 2032 from $915.2 million in 2021 at a CAGR of 15.93% during the forecast period 2022-2032. This The market is driven by certain factors, such as low satisfaction with available therapies, robust pipeline products, rising uptake of narcolepsy awareness programs, and improving diagnosis. Recent Developments in the Global Narcolepsy Therapeutics Market • On March 28, 2022, Jazz Pharmaceuticals PLC divested Sunosi. Axsome Therapeutics, Inc. intends to expand its presence in neuroscience by acquiring Sunosi (solriamfetol) from Jazz Pharmaceuticals PLC. • On August 31, 2021, Health Canada approved Jazz Pharmaceutical’s Sunosi (solriamfetol) for excessive daytime sleepiness associated with narcolepsy. • On August 10, 2021, Harmony Biosciences LLC’s successful track record of Wakix motivated Blackstone to enter a strategic financing collaboration, where the company agreed to invest up to $330.0 million of financing and growth capital in Harmony Biosciences LLC. • On September 16, 2021, Axsome Therapeutics, Inc. announced the enrollment of the first patient in the new phase 3 clinical trial SYMPHONY (a study evaluating a mechanistic approach to treating narcolepsy) of AXS-12 in narcoleptic patients. Market segmentation Segmentation 1: by indication • Type 1 narcolepsy • Type 2 narcolepsy • Secondary narcolepsy Due to recent research and development in type 1 narcolepsy, significant therapies with novel mechanisms of action, reduced dosage, and better efficacy are emerging. Therefore, the segment is dominated by type 1 narcolepsy, which held a share of 69.60% in 2021. Segmentation 2: by product • commercialized products • pipeline products In 2021, the global narcolepsy therapeutics market (by product) is dominated by commercialized products with 100% market share. Segmentation 3: by Therapeutic Type • Central Nervous System Stimulant • Norepinephrine Reuptake Inhibitor • Histamine-3 (H3) Receptor Antagonist/Inverse Agonist The global narcolepsy therapeutics market (by therapeutics) is currently dominated by central nervous system stimulants, with a value of $535.3 million, as of 2021. Segmentation 4: by Country • US • Germany • Italy • France • UK • Spain • Japan In 2021, the US accounted for a share of 93.48% of the global narcolepsy therapeutics market. The segment is expected to reach $4,327.7 million in 2032 from $855.5 million in 2021 at a CAGR of 15.24% during the forecast period 2022-2032 Key Market Players and Competition Synopsis The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration. Some of the prominent names established in this market are: Jazz Pharmaceuticals PLC Harmony Bioscience, LLC Axsome Therapeutics, Inc. Avadel Pharmaceuticals PLC Takeda Pharmaceutical Co Ltd Sumitomo Pharma Co Ltd Suven Life Sciences Limited NLS Pharmaceutics AG Balance Therapeutics